Pages
-
-
Adherence to treat-to-target management in rheumatoid arthritis and associated factors
-
-
Outcomes and findings of the international rheumatoid arthritis (RA) BIODAM cohort for validation of soluble biomarkers in RA
-
-
Is treat-to-target really working in rheumatoid arthritis?
-
-
Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire
-
-
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
-
-
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
-
-
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
-
-
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
-
-
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
-
-
INDUCTION OF SUSTAINED REMISSION IN EARLY INFLAMMATORY ARTHRITIS WITH THE COMBINATION OF INFLIXIMAB PLUS METHOTREXATE, METHOTREXATE ALONE OR PLACEBO: THE DINORA TRIAL
-
-
The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis
-
-
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
-
-
IS TREAT-TO-TARGET REALLY WORKING? A LONGITUDINAL ANALYSIS IN BIODAM
-
-
Is Treat-to-Target Really Working? a Longitudinal Analysis in Biodam
-
-
14-3-3 eta Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
-
-
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
-
-
TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits
-
-
A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides
-
-
Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model
-
-
CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis
-
-
14-3-3 eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage
-
-
Serum 14-3-3 eta is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
-
-
Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program
-
-
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Pages
